Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy
Aging and disease · 2025
DOI: 10.14336/ad.2024.1688 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Aging and disease, 2025. Verfasst von Weiyue Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Biological Science and Medical Engineering, Beihang University, B…. Hauptthemen laut MEDLINE: Thrombosis, Fibrinolytic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 266 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
In clinical practice, antiplatelet, anticoagulant and fibrinolytic drugs are the mainstay of thrombosis treatment, but their potential bleeding side effects limit their widespread use. Therefore, modifying these existing drugs or developing new therapies that mitigate bleeding risks while maintaining their efficacy and utilization is necessary. Since the critical role of platelets in thrombosis is closely related to their cell surface receptors, intracellular signaling pathways and metabolism, current research focuses on these three major classes of platelet targets to develop new antithrombotic drugs. The coagulation cascade has always been the main target of anticoagulant drugs, but since the role of molecules of the contact system is more critical in thrombosis than in hemostasis, molecules targeting the contact system, such as FXIa and FXIIa, have become the main direction of anticoagulant drug research at present. Moreover, since the inflammatory response has been found to be significantly associated with thrombosis in recent years, the development of drugs that target inflammatory pathways, such as inflammasome, has also become a hot topic. This article provides a detailed description of these targets or drug formulations that are currently being investigated, including their mode of action and antithrombotic efficiency, and also points out their existing shortcomings. Moreover, antithrombotic nanomedicines can achieve precise release of drugs, which can greatly improve the thrombolytic efficiency and reduce side effects. In conclusion, this review focuses on summarizing the current new targets and new methods of antithrombotic drug research, hoping to provide a little reference for future related research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Biological Science and Medical Engineering, Beihang University, Beijing, 100191, China.
- Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Beijing Advanced Innovation Center for Big Data-Based Precisi…
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Zitieren
APA
Zhang, W., Pei, B., Zhou, Y., Li, H., Ma, W., Zhou, B., Zhou, C., Jiang, H., & Ji, X. (2025). Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy. Aging and disease. https://doi.org/10.14336/ad.2024.1688
Vancouver
Zhang W, Pei B, Zhou Y, Li H, Ma W, Zhou B, et al. Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy. Aging and disease. 2025. doi:10.14336/ad.2024.1688
BibTeX
@article{Zhang2025,
author = {Zhang, Weiyue and Pei, Baoqing and Zhou, Yifan and Li, Hui and Ma, Wei and Zhou, Bing and Zhou, Chen and Jiang, Huimin and Ji, Xunming},
title = {Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy},
journal = {Aging and disease},
year = {2025},
doi = {10.14336/ad.2024.1688}
}
EUVIMED